PMID- 37750029
OWN - NLM
STAT- MEDLINE
DCOM- 20240130
LR  - 20240131
IS  - 1753-0407 (Electronic)
IS  - 1753-0393 (Print)
IS  - 1753-0407 (Linking)
VI  - 16
IP  - 1
DP  - 2024 Jan
TI  - Ten-year clinical characteristics of patients with early-onset type 2 diabetes: A 
      single-center experience in China.
PG  - e13477
LID - 10.1111/1753-0407.13477 [doi]
LID - e13477
AB  - AIMS: The incidence of type 2 diabetes in China has exhibited an increasing 
      trend, including younger individuals, over the past years. Early-onset type 2 
      diabetes (EOT2D) refers to diabetes diagnosed before 40 years of age. These 
      patients have poor metabolic control and are highly susceptible to diabetic 
      complications, which poses challenges for treatment. However, few studies have 
      reported on the treatment of EOT2D. We determined clinical features and trends in 
      drug use in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: 
      This retrospective study was performed at the Endocrinology Ward, Peking Union 
      Medical College Hospital (PUMCH). "Diabetes" was used when searching PUMCH's 
      Electronic Medical Record Analytical Database to obtain clinical data of patients 
      between January 2013 and May 2022. RESULTS: The analysis included 1590 patients 
      with T2DM. Among them, 609 (38.3%) had EOT2D. Compared with late-onset type 2 
      diabetes (LOT2D) patients, EOT2D patients exhibited worse glycemic control and 
      higher body weight and lipid levels despite significant age differences. EOT2D 
      patients also had a higher risk of diabetic retinopathy and nephropathy. Under 
      the general trend of increasing use of dipeptidylpeptidase-4 inhibitors, 
      sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists, 
      patients with EOT2D were more likely to use organ-protective drugs. CONCLUSIONS: 
      Compared with LOT2D patients, EOT2D patients have a longer course of diabetes, 
      worse metabolic control, and a higher rate of developing microvascular 
      complications. The administration of combined therapy, including new agents, may 
      require consideration when selecting hypoglycemic agents for treating EOT2D.
CI  - (c) 2023 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai 
      Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
FAU - Yu, Ruiqi
AU  - Yu R
AUID- ORCID: 0000-0001-8260-9853
AD  - National Health Commission (NHC) Key Laboratory of Endocrinology, Diabetes 
      Research Center of Chinese Academy of Medical Sciences, Department of 
      Endocrinology, Peking Union Medical College Hospital, Peking Union Medical 
      College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Liu, Xiaoyu
AU  - Liu X
AD  - National Health Commission (NHC) Key Laboratory of Endocrinology, Diabetes 
      Research Center of Chinese Academy of Medical Sciences, Department of 
      Endocrinology, Peking Union Medical College Hospital, Peking Union Medical 
      College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Li, Ruochen
AU  - Li R
AD  - National Health Commission (NHC) Key Laboratory of Endocrinology, Diabetes 
      Research Center of Chinese Academy of Medical Sciences, Department of 
      Endocrinology, Peking Union Medical College Hospital, Peking Union Medical 
      College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Xiao, Xinhua
AU  - Xiao X
AD  - National Health Commission (NHC) Key Laboratory of Endocrinology, Diabetes 
      Research Center of Chinese Academy of Medical Sciences, Department of 
      Endocrinology, Peking Union Medical College Hospital, Peking Union Medical 
      College, Chinese Academy of Medical Sciences, Beijing, China.
LA  - eng
GR  - Z201100005520011/Beijing Municipal Science and Technology Commission, 
      Adminitrative Commission of Zhongguancun Science Park/
GR  - 7202163/Beijing Natural Science Foundation/
GR  - CIFMS2021-1-I2M-002/CAMS Innovation Fund for Medical Sciences/
GR  - 2022-PUMCH-C-019/National High Level Hospital Clinical Research Funding/
GR  - 2022-PUMCH-B-121/National High Level Hospital Clinical Research Funding/
GR  - 82170854/National Natural Science Foundation of China/
GR  - 81170736/National Natural Science Foundation of China/
GR  - 81570715/National Natural Science Foundation of China/
GR  - 81870545/National Natural Science Foundation of China/
GR  - 81870579/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230926
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology/complications
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Diabetic Retinopathy/complications
PMC - PMC10809291
OTO - NOTNLM
OT  - antidiabetic drugs
OT  - drug utilization
OT  - early-onset type 2 diabetes
OT  - glycemic control
COIS- The authors declare that they have no conflict of interest.
EDAT- 2023/09/26 06:44
MHDA- 2024/01/30 12:44
PMCR- 2023/09/26
CRDT- 2023/09/26 03:10
PHST- 2023/07/31 00:00 [revised]
PHST- 2023/04/24 00:00 [received]
PHST- 2023/09/04 00:00 [accepted]
PHST- 2024/01/30 12:44 [medline]
PHST- 2023/09/26 06:44 [pubmed]
PHST- 2023/09/26 03:10 [entrez]
PHST- 2023/09/26 00:00 [pmc-release]
AID - JDB13477 [pii]
AID - 10.1111/1753-0407.13477 [doi]
PST - ppublish
SO  - J Diabetes. 2024 Jan;16(1):e13477. doi: 10.1111/1753-0407.13477. Epub 2023 Sep 
      26.